The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Redefining outcomes in R/R myeloma in an era of novel therapies
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the redefinition of outcomes in relapsed/refractory multiple myeloma (R/R MM) due to the emergence of novel agents, highlighting the importance of considering not only efficacy but also treatment safety, quality of life, and patient preferences. Dr Ocio notes that the growing number of treatment options allows for a more personalized approach that considers individual patient needs, family support, and lifestyle. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
